US 2017/0362633 A1 · NRAS RELATED CANCER THERAPY

Abstract

The present invention encompasses the recognition that identification of alternative means to block RAS oncogenic signaling may be required for developing novel cancer therapies. Among other things, the present invention encompasses the recognition that targeting RAS palmitoylation can achieve effective therapy for RAS-related cancers. Furthermore, the present invention encompasses the recognition that reduction of ZDHHC9 level and/or activity can significantly reduce palmitoylation level of Ras protein. Among other things, the present invention encompasses the recognition that identification of agents that modulate expression and/or activity of ZDHHC9 can reduce palmitoylation level of Ras protein. In some embodiments, the present invention provides methods of treating a subject suffering from cancer by administering ZDHHC9 inhibition therapy.

Claims34

Dependent claims

A method of identifying one or more ZDHHC9 inhibitors:

contacting a model system in which ZDHHC9 activity, or a proxy thereof, is detectable with a plurality of test agents;
detecting ZDHHC9 activity, or the proxy thereof, in the model system when each test agent is present;
comparing detected ZDHHC9 activity, or the proxy thereof, to an appropriate reference ZDHHC9 activity or proxy thereof;
identifying a test agent as ZDHHC9 inhibitor when the detected activity or proxy thereof is reduced relative to the reference activity or proxy thereof.

1 more element

Dependencies are inferred from the claim text.

Nras related cancer therapy

Life of this patent

Nras related cancer therapy

Life of this patent

Abstract

Claims34